** Shares of drug developer Inovio Pharmaceuticals Inc
INO.O up 3.59% at $12.4 premarket
** INO announces deal with Kaneka Eurogentec S.A., an
affiliate of Japan's Kaneka Corp 4118.T , to make INO's
COVID-19 vaccine candidate INO-4800; deal terms were not
disclosed urn:newsml:reuters.com:*:nPn9ZPgd2a
** INO has already partnered with Thermo Fisher Scientific,
Richter-Helm BioLogics and Ology Biosciences to manufacture the
potential vaccine
** Co is currently running the Phase 2 segment of its
planned Phase 2/3 clinical trial for INO-4800 against COVID-19
urn:newsml:reuters.com:*:nL4N2I22ZI
** The U.S. FDA in September had put the Phase 3 portion of
the mid-to-late stage trial on hold, as it sought more
information, including details on a delivery device
** Up to Wednesday's close, INO up ~263% YTD
(Reporting by Manojna Maddipatla in Bengaluru)
((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91 80 6749 1692))